dc.contributor.author | Marchesi, F. | |
dc.contributor.author | Salmanton-García, J. | |
dc.contributor.author | Emarah, Z. (...) | |
dc.contributor.author | Stoma, I. [et al.] | |
dc.date.accessioned | 2022-08-01T07:50:17Z | |
dc.date.available | 2022-08-01T07:50:17Z | |
dc.date.issued | 2023 | |
dc.identifier.citation | COVID-19 in adult acute myeloid leukemia patients: a long-term followup study from the European Hematology Association survey (EPICOVIDEHA) / F. Marchesi, J. Salmanton-García, Z. Emarah (...), I. Stoma [et al.] // Haematologica. – 2023. – Vol. 108, № 1. – P. 22–33. | ru_RU |
dc.identifier.uri | http://elib.gsmu.by/handle/GomSMU/11913 | |
dc.description.abstract | Patients with acute myeloid leukemia (AML) are at high risk of mortality from coronavirus disease 2019 (COVID-19). The optimal management of AML patients with COVID-19 has not been established. Our multicenter study included 388 adult AML patients with COVID-19 diagnosis between February 2020 and October 2021. The vast majority were receiving or had received AML treatment in the prior 3 months. COVID-19 was severe in 41.2% and critical in 21.1% of cases. The chemotherapeutic schedule was modified in 174 patients (44.8%), delayed in 68 and permanently discontinued in 106. After a median follow-up of 325 days, 180 patients (46.4%) had died; death was attributed to COVID-19 (43.3%), AML (26.1%) or to a combination of both (26.7%), whereas in 3.9% of cases the reason was unknown. Active disease, older age, and treatment discontinuation were associated with death, whereas AML treatment delay was protective. Seventy-nine patients had a simultaneous AML and COVID-19 diagnosis, with an improved survival when AML treatment could be delayed (80%; p<0.001). Overall survival in patients with COVID-19 diagnosis between January 2020 and August 2020 was significantly lower than those who were diagnosed between September 2020 and February 2021 and between March 2021 and September 2021 (39.8% vs 60% vs 61.9%, respectively; p=0.006). COVID-19 in AML patients was associated with a high mortality rate and modifications of therapeutic algorithms. The best approach to improve survival was to delay AML treatment, whenever possible. | ru_RU |
dc.language.iso | en_US | ru_RU |
dc.publisher | Haematologica | ru_RU |
dc.subject | COVID-19 | ru_RU |
dc.subject | acute myeloid leukemia | ru_RU |
dc.subject | European Hematology Association | ru_RU |
dc.title | COVID-19 in adult acute myeloid leukemia patients: a long-term followup study from the European Hematology Association survey (EPICOVIDEHA) | ru_RU |
dc.type | Article | ru_RU |
dc.identifier.doi | https://doi.org/10.3324/haematol.2022.280847 | |